All In Biotech

Drug Trial Radar · NCT07548840

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

An Open-label, Single-arm Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

34

Actual

Start

May 8, 2026

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on hemodialysis

Conditions

  • Hyperphosphatemia Patients on Hemodialysis

Interventions

  • TS-172 20~60 mg/dayDrug

    oral administration of TS-172 20\~60 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement rate of the target serum phosphorus levelTime frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taisho selected site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.